Top Markets
Coin of the day
Voronoi, Inc. Voronoi, Inc.

Voronoi, Inc.

310210
Rank in Stocks #6296
Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a... Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a biotechnology company dedicated to the research, development, and identification of small molecule kinase inhibitors. Its extensive product pipeline addresses various medical needs. Key candidates include VRN01, an oral leucine-rich repeat kinase 2 (LRRK2) inhibitor, being developed for glioblastoma multiforme, brain cancer, and pancreatic cancer. Treatments for lung cancer are represented by VRN07, VRN06, and VRN11, while VRN08 and VRN10 are in development for breast cancer. Additionally, VRN02 targets rheumatoid arthritis and atopic dermatitis. The company's pipeline further encompasses VRN04-1 for autoimmune conditions, VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis (ALS), VRN13 for pulmonary arterial hypertension, and VRN14 for challenging solid tumors.
Share Price
$115.48
Market Cap
$2.12B
Change (1 day)
0.72%
Change (1 year)
29.38%
Country
KR
Trade Voronoi, Inc. (310210)

Category

P/S ratio for Voronoi, Inc. (310210)
P/S ratio as of 2026 TTM: 0
According to Voronoi, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Voronoi, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH